Chronic Myelod Leukemia Registry at Asan Medical Center

Study Overview
=================
Brief Summary
-----------------
The investigators would like to propose a prospective longitudinal observational cohort study for patients who will be diagnosed and/or treated for chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, to use the acquired data for fundamentals of other retrospective analysis.

Detailed Description
-----------------
Acquisition of informed concent form Data acquisition from medical record including demographic / disease-associated factors details of treatment, and its results complications during treatment genetic data survival outcome (upto 30 years) Accumulation of data for 30 years Use of data for other retrospective analysis (including Asan Medical center Cell Banking basic data)

Official Title
-----------------
Prospective Observational Cohort Registry for Patients With Chronic Myeloid Leukemia at Asan Medical Center

Conditions
-----------------
Leukemia, Chronic Myeloid, Myeloid Leukemia, Chronic, Accelerated Phase, Myeloid Leukemia, Chronic, Chronic Phase

Intervention / Treatment
-----------------
* Other: Diagnosed as CML


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who are diagnosed and/or treated as chronic myeloid leukemia at Asan Medical Center 15 years of age and over All patients who give written consent according to guidelines at Asan Medical Center committee on human research Exclusion Criteria: Patients who refuse to give consent to registering

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CML CP<br>Diagnosed as CML with chronic phase | Other: Diagnosed as CML<br>* All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047<br>* Other names: Diagnosed as chronic myeloid leukemia;|
| CML AP<br>Diagnosed as CML with accelerated phase | Other: Diagnosed as CML<br>* All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047<br>* Other names: Diagnosed as chronic myeloid leukemia;|
| CML BC<br>Diagnosed as CML with blast crisis | Other: Diagnosed as CML<br>* All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047<br>* Other names: Diagnosed as chronic myeloid leukemia;|
| CML other<br>Diagnosed as CML, which is not included in any of other category | Other: Diagnosed as CML<br>* All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047<br>* Other names: Diagnosed as chronic myeloid leukemia;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 30 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Event-free survival | Definition of events will be as 'failure', 'progress to AP/BC', 'intolerant and medication change', and 'death from any cause'. | 30 years | 
| Failure-free survival | Failure will be defined as BCR-ABL elevation at 2 serial times, progression to AP/BC, loss of hematologic / cytogenetic response, any appearance of ABL kinase mutation, and clonal evolution. | 30 years |